UNLIMITED TURBO SHORT - BRISTOL-MYERS SQUIBB | Market Closed - Bid/Ask 02:50:31 2024-07-11 pm EDT | ||
| 1.14 EUR | +1.79% |
|
| Current month | -1.75% | ||
| 1 month | +10.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 1.14 | +1.79% |
| 24-07-10 | 1.12 | -1.75% |
| 24-07-09 | 1.14 | -7.32% |
| 24-07-08 | 1.23 | -1.60% |
| 24-07-05 | 1.25 | +2.46% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 02:50 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC7K45 |
| ISIN | DE000PC7K459 |
| Date issued | 2024-04-03 |
| Strike | 52.99 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.28 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.01 € |
| Spread % | 0.87% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.12
USD
Average target price
52.92
USD
Spread / Average Target
+28.70%
- Stock Market
- Certificates
- Certificat
